

$Y^1, Y^2, Y^3$  and  $Y^4$  are each independently selected from:  $-\text{CH}-$ ,  $-\text{CF}-$ ,  $-\text{C}(\text{NHCOCH}_3)-$ ,  $-\text{C}(\text{NHCOC}_2\text{H}_5)-$  and  $-\text{N}-$ ,

with the proviso that not all of Y<sup>1</sup> to Y<sup>4</sup> are simultaneously nitrogen atoms;

Ar is a benzene ring, a pyridine ring, a pyrazine ring or a pyrimidine ring, unsubstituted or substituted with one or two substituents selected from Group  $\beta$ :

each Group  $\alpha$  is independently selected from: halogen, hydroxyl, amino, nitro, oxo, mono-lower alkylamino, di-lower alkylamino, optionally halogen-substituted lower alkyl, optionally fluorine-substituted lower alkyloxy, lower cycloalkyloxy, lower alkyloxycarbonyl, (lower alkyloxycarbonyl)amino, (lower alkyloxycarbonyl) lower alkylamino, lower alkylcarbonyl, lower alkylcarbonyloxy, (lower alkylcarbonyl)amino, (lower alkylcarbonyl) lower alkylamino, carbamoyl, mono-lower alkylcarbamoyl, di-lower alkylcarbamoyl, carbamoylamino, mono-lower alkylcarbamoylamino, di-lower alkylcarbamoylamino, (mono-lower alkylcarbamoyl) lower alkylamino, (di-lower alkylcarbamoyl) lower alkylamino, carbamoyloxy, mono-lower alkylcarbamoyloxy, di-lower alkylcarbamoyloxy, lower alkylsulfonyl, lower alkylsulfonylamino, sulfamoyl, mono-lower alkylsulfamoyl, di-lower alkylsulfamoyl, sulfamoylamino, (mono-lower alkylsulfamoyl)amino, (di-lower alkylsulfamoyl)amino, (mono-lower alkylsulfamoyl) lower alkylamino and (di-lower alkylsulfamoyl) lower alkylamino; and

each Group  $\beta$  is independently selected from: nitro, aryloxy, lower cycloalkyl, lower cycloalkyloxy, lower alkylenedioxy, halogen, hydroxyl, optionally hydroxyl- or fluorine-substituted lower alkyl and optionally fluorine-substituted lower alkyloxy.

Claim 34. (Previously Presented) The compound according to Claim 33, wherein R<sup>1a</sup> is hydrogen, methyl or hydroxyl; and pharmaceutically acceptable salts thereof.

Claim 35. (Cancelled).

Claim 36. (Previously Presented) The compound according to Claim 33, wherein both R<sup>3a</sup> and R<sup>3b</sup> are hydrogen atoms; and pharmaceutically acceptable salts thereof.

Claim 37. (Previously Presented) The compound according to Claim 33, wherein R<sup>4a</sup> and R<sup>4b</sup> are selected from the group consisting of hydrogen, fluorine and hydroxyl; and pharmaceutically acceptable salts thereof.

Claim 38. (Previously Presented) The compound according to Claim 33, wherein R<sup>5a</sup> and R<sup>5b</sup> are hydrogen or methyl; and pharmaceutically acceptable salts thereof.

Claim 39. (Previously Presented) The compound according to Claim 33, wherein each  $R^6$  is hydrogen; and pharmaceutically acceptable salts thereof.

Claims 40 and 41. (Cancelled).

Claim 42. (Previously Presented) The compound according to Claim 33, wherein CY is a substituent selected from the group consisting of phenyl, 4-fluorophenyl, 4-chlorophenyl, 3,4-difluorophenyl, 4-methoxyphenyl, 4-tolyl, 4-trifluoromethylphenyl, pyridinyl, pyridin-3-yl, pyrazinyl, pyrimidinyl, 6-fluoropyridin-3-yl, 2-fluoropyridin-4-yl, 6-trifluoromethylpyridin-3-yl, 6-methoxypyridin-3-yl, pyrrol-1-yl, pyrazolyl, imidazolyl, 2-methylimidazolyl, 4-methylimidazolyl, 1,2,3-triazol-1-yl, 4-methyl-1,2,3-triazol-1-yl, 1,2,4-triazol-1-yl, 1,2,3,4-tetrazol-1-yl, 1,2,3,4-tetrazol-2-yl, thiazolyl, pyrrolidin-1-yl, piperidinyl, 2-piperidon-1-yl, 2-pyridon-1-yl, 2-pyrrolidon-1-yl, oxazolidin-2-on-1-yl, 4-methanesulfonyl-piperazin-2-on-1-yl, cyclohexyl and cyclopentyl; or a pharmaceutically acceptable salt thereof.

Claim 43. (Cancelled).

Claim 44. (Previously Presented) The compound according to Claim 33, wherein Ar is a substituent selected from the group consisting of phenyl, 4-fluorophenyl, 3,4-difluorophenyl, 4-chlorophenyl, 4-methoxyphenyl, 4-tolyl, 4-trifluoromethylphenyl, pyridinyl, 6-fluoropyridin-3-yl, 6-trifluoromethylpyridin-3-yl, and 6-methoxypyridin-3-yl; and pharmaceutically acceptable salts thereof.

Claim 45. (Currently Amended) The compound according to Claim 33 selected from the group consisting of:


- (1) 2-(3,4-difluorophenyl)-2-(2-oxo-1-pyrrolidinyl)-N-[3-(spiro[5-fluoroisobenzofuran-1(3H), 4'-piperidin]-1-yl)propyl]acetamide;
- (2) 2-(3,4-difluorophenyl)-N-methyl-2-(1H-1,2,3-triazol-1-yl)-N-[3-(spiro [isobenzofuran-1(3H), 4'-piperidin]-1-yl)propyl]acetamide,
- (2)(3) 2-(3,4-difluorophenyl)-N-methyl-2-(2H-1,2,3,4-tetrazol-2-yl)- N-[3-(spiro[isobenzofuran-1(3H), 4'-piperidin]-1-yl)propyl]acetamide,
- (3)(4) 2-(3,4-difluorophenyl)-N-methyl-2-(2-oxo-1(2H)pyridinyl)-N-[3-(spiro[isobenzofuran-1(3H), 4'-piperidin]-1-yl)propyl]acetamide,

(4)(5) 2-(3,4-difluorophenyl)-N-methyl-2-(2-oxo-1- pyrrolidinyl)-N- [3-(spiro[5-fluoroisobenzofuran-1(3H),4'-piperidin]-1-yl)propyl]-acetamide,  
(5)(6) 2-(3,4-difluorophenyl)-N-methyl-2-(2-methyl-1H-imidazol-1- yl)-N-[3-(spiro[6-fluoroisobenzofuran-1(3H),4'-piperidin]-1-yl)propyl]-acetamide,  
(6)(7) 2-(3,4-difluorophenyl)-N-methyl-2-(2-methyl-1H-imidazol-1- yl)-N-[3-(spiro[5-fluoro-6-azaisobenzofuran-1(3H),4'-piperidin]-1-yl)propyl]acetamide,  
(7)(8) 2,2-bis(6-fluoro-3-pyridinyl)-N-methyl-N-[3-(spiro[5-fluoro-6- azaisobenzofuran-1(3H),4'- piperidin]-1-yl)propyl]acetamide,  
(8)(9) 2-(3,4-difluorophenyl)-N-ethyl-2-(2-oxo-1-pyrrolidinyl)-N- [3-(spiro[isobenzofuran-1(3H),4'-piperidin]-1-yl)propyl]acetamide,  
(9)(+0) 2-(3,4-difluorophenyl)-N-ethyl-2-(4-methanesulfonyl)-2-oxo- 1-piperazinyl)-N-[3-(spiro[6-fluoroisobenzofuran-1(3H),4'-piperidin]-1-yl)propyl]acetamide, and  
or a pharmaceutically acceptable salt thereof.


Claims 46-52. (Cancelled).

Claim 53. (Previously Presented) A method for producing a compound according to Claim 33 of general formula [I-1], which comprises:

(1) amidating a compound represented by a general formula [IIa]:



wherein  $R^2$ ,  $R^{3a}$ ,  $R^{3b}$ ,  $R^{4a}$ ,  $R^{4b}$ ,  $R^{5a}$ ,  $R^{5b}$ ,  $R^6$ ,  $Y^1$ ,  $Y^2$ ,  $Y^3$ ,  $Y^4$ ,  $W^3$ ,  $W^4$  and  $n$  are as in Claim 33, with a compound represented by a general formula (IIIa)



wherein: Ar, R<sup>1a</sup> and CY are as in Claim 33.

Claims 54-57. (Cancelled).

Claim 58. (Previously Presented) The compound according to Claim 57 selected from the group consisting of:

- (1) 2-(4-fluorophenyl)-N-methyl-2-(2-oxo-1-pyrrolidinyl)-N-[3-(spiro[6-azaisobenzofuran-1(3H), 4'-piperidin]-1-yl)propyl]acetamide,
- (2) 2-(3,4-difluorophenyl)-N-methyl-2-(2-oxo-1-pyrrolidinyl)-N-[3-(spiro[5-fluoro-6-azaisobenzofuran-1(3H), 4'-piperidin]-1-yl)propyl]acetamide,
- (3) 2-(3,4-difluorophenyl)-N-methyl-2-(2-oxo-1-pyrrolidinyl)-N-[3-(spiro[6-fluoro-5-azaisobenzofuran-1(3H), 4'-piperidin]-1-yl)-propyl]acetamide,
- (4) 2-(3,4-difluorophenyl)-N-methyl-2-(2-methyl-1H-imidazol-1-yl)-N-[3-(spiro[5-fluoro-6-azaisobenzofuran-1(3H), 4'-piperidin]-1-yl)-propyl]acetamide,
- (5) 2-(3,4-difluorophenyl)-2,2-dimethyl-N-methyl-N-[3-(spiro[5-fluoro-6-azaisobenzofuran-1(3H), 4'-piperidin]-1-yl)propyl]acetamide,
- (6) 2-(3,4-difluorophenyl)-N-methyl-2-(1H-1,2,4-triazol-1-yl)-N-[3-(spiro[5-fluoro-6-azaisobenzofuran-1(3H), 4'-piperidin]-1-yl)propyl]-acetamide,
- (7) 2,2-bis(6-fluoro-3-pyridinyl)-N-methyl-N-[3-(spiro[5-fluoro-6-azaisobenzofuran-1(3H), 4'-piperidin]-1-yl)propyl]-acetamide,
- (8) N-methyl-2,2-bis(6-methoxy-3-pyridinyl)-N-[3-(spiro[5-fluoro-6-azaisobenzofuran-1(3H), 4'-piperidin]-1-yl)propyl]acetamide,
- (9) 2-(6-fluoro-3-pyridinyl)-2-(4-fluorophenyl)-N-methyl-N-[3-(spiro[5-fluoro-6-azaisobenzofuran-1(3H), 4'-piperidin]-1-yl)propyl]-acetamide,
- (10) 2-(6-fluoro-3-pyridinyl)-N-methyl-2-(6-trifluoromethyl-3-pyridinyl)-N-[3-(spiro[5-fluoro-6-azaisobenzofuran-1(3H), 4'-piperidin]-1-yl)propyl]acetamide,
- (11) 2-(6-fluoro-3-pyridinyl)-2-(6-methoxy-3-pyridinyl)-N-methyl-N-[3-(spiro[5-fluoro-6-azaisobenzofuran-1(3H), 4'-piperidin]-1-yl)-propyl]acetamide,
- (12) 2-(6-fluoro-3-pyridinyl)-2-(4-tolyl)-N-methyl-N-[3-(spiro[5-fluoro-6-azaisobenzofuran-1(3H), 4'-piperidin]-1-yl)propyl]-acetamide,
- (13) 2-(6-fluoro-3-pyridinyl)-N-methyl-2-phenyl-N-[3-(spiro[5-fluoro-6-azaisobenzofuran-1(3H), 4'-piperidin]-1-yl)propyl]-acetamide,
- (14) 2,2-bis(4-fluorophenyl)-N-methyl-N-[3-(spiro[5-fluoro-6-azaisobenzofuran-1(3H), 4'-piperidin]-1-yl)propyl]acetamide,

- (15) 2-(3,4-difluorophenyl)-N-methyl-2-(1H-pyrrol-1-yl)-N-[3-(spiro[5-fluoro-6-azaisobenzofuran-1(3H),4'-piperidin]-1-yl)propyl]-acetamide,
- (16) 2-(4-fluorophenyl)-N-methyl-2-(1H-pyrrol-1-yl)-N-[3-(spiro[5-fluoro-6-azaisobenzofuran-1(3H), 4'-piperidin]-1-yl)propyl]acetamide,
- (17) 2-(3,4-difluorophenyl)-N-methyl-2-(1H-pyrazol-1-yl)-N-[3-(spiro[5-fluoro-6-azaisobenzofuran-1(3H), 4'-piperidin]-1-yl)propyl]-acetamide,
- (18) 2-(3,4-difluorophenyl)-N-methyl-2-(1H-pyrrol-1-yl)-N-[3-(spiro[6-fluoro-5-azaisobenzofuran-1(3H),4'-piperidin]-1-yl)propyl]-acetamide,
- (19) 2-(6-fluoro-3-pyridinyl)-2-(4-fluorophenyl)-N-methyl-N-[3-(spiro[6-fluoro-5-azaisobenzofuran-1(3H),4-piperidin]-1-yl)propyl]-acetamide,
- (20) 2-(6-fluoro-3-pyridinyl)-2-(4-fluorophenyl)-N-methyl-N-[3-(spiro[6-azaisobenzofuran-1(3H),4-piperidin]-1-yl)propyl]acetamide,
- (21) 2,2-bis(6-fluoro-3-pyridinyl)-N-ethyl-N-[3-(spiro[5-fluoro-6-azaisobenzofuran-1(3H), 4'-piperidin]-1-yl)-propyl]acetamide,
- (22) 2-(6-fluoro-3-pyridinyl)-2-(2,4-difluorophenyl)-2-hydroxy-N-methyl-N-[3-(spiro[6-fluoro-5-azaisobenzofuran-1(3H),4'-piperidin]-1-yl)propyl]acetamide,
- (23) 2-(2,4-difluorophenyl)-2-(6-fluoro-3-pyridinyl)-2-hydroxy-N-methyl-N-[3-(spiro[6-azaisobenzofuran-1(3H), 4'-piperidin]-1-yl)propyl]acetamide, or
- (24) 2,2-bis(4-fluorophenyl)-2-hydroxy-N-methyl-N-[3-(spiro[5-fluoro-6-azaisobenzofuran-1(3H), 4'-piperidin]-1-yl)propyl]acetamide,

or a pharmaceutically acceptable salt thereof.

Claim 59. (Cancelled).